Download PDF
Thromb Haemost 1963; 10(02): 355-378
DOI: 10.1055/s-0038-1654790
Originalarbeiten — Original Article — Travaux Originaux
Schattauer GmbH

Les inhibiteurs de la fibrinolyse et le dosage de l’activité antiplasminique physiologique et pathologique

M Moriau
1   Laboratoire de la Transfusion Sanguine et d}Hématologie du Wilhelmina Gasthuis, Amsterdam (Directeur: Dr. S. 1. de Vries)
,
S. I de Vries
1   Laboratoire de la Transfusion Sanguine et d}Hématologie du Wilhelmina Gasthuis, Amsterdam (Directeur: Dr. S. 1. de Vries)
,
H. J Dik
1   Laboratoire de la Transfusion Sanguine et d}Hématologie du Wilhelmina Gasthuis, Amsterdam (Directeur: Dr. S. 1. de Vries)
› Author Affiliations
Further Information

Publication History

Publication Date:
22 June 2018 (online)

    Permissions and Reprints

Résumé

Dans cet exposé une technique de dosage quantitatif de l’activité antiplas-minique sérique a été décrite. Ses variations sur 100 sujets normaux et dans certaines affections on été envisagées. Un dosage de l’activité antiplasminique pla-quettaire a été réalisé chez un certain nombre de patients présentant une thrombopathie liée à une myélofibrose ou polycythémie. Le fractionnement électro-phorétique ou au Rivanol des protéines du sérum ou d’un extrait plaquettaire normal a permis de localiser l’activité antiplasminique au sein des fractions alpha1-, alpha2-et gammaglobulines, et l’activité antitrypsique au sein de la fraction alpha1-globuline. Diverses propriétés de certaines antiplasmines non sanguines ont également été mentionnées.

 

  • Bibliographie

  • 1 Adamis D, Stefanini M, Gagliano A. A simplified method for the determination of antiplasmin activity in human serum. Fed. Proc. 20: 59 1961;
    PubMedGoogle Scholar
  • 2 Astrup T, Alkjaersig N. Classification of proteolytic enzymes by means of their inhibitors. Nature. 196: 314 1952;
    PubMedGoogle Scholar
  • 3 Astrup T, Miillertz S. The fibrin plate method for estimating fibrinolytic activity. Biochim. biophys. Acta. 40: 346 1962;
    PubMedGoogle Scholar
  • 4 Astrup T, Brakman P, Ollendorff P, Rasmussen J. Hemostasis in hemophilia in relation to the hemostatic balance in the normal organism and the effect of pea-nuts. Thrombos. Diathes. haemorrh. (Stuttg..) 05: 329 1960;
    PubMedGoogle Scholar
  • 5 Bickford J. F. A, Sokolow M. Fibrinolysis as related to the urea solubility of fibrin. Thrombos. Diathes. haemorrh. (Stuttg..) 05: 480 1961;
    PubMedGoogle Scholar
  • 6 Blix S. Antibodies after streptokinase treatment and importance for repeated fibrinolytic therapy. Acta med. scand. 170: 201 1961;
    PubMedGoogle Scholar
  • 7 Christensen L. R. Streptococcal fibrinolysis. A proteolytic reaction due to serum enzyme activated by streptococcal fibrinolysin. J. gen. Physiol. 28: 363 1945;
    PubMedGoogle Scholar
  • 8 Dausset J, Bergerot-Blondel Y, Colin M. Acceleration of fibrinolysis of blood clot dilution with saline and human serum. Lancet. II: 123 1956;
    PubMedGoogle Scholar
  • 9 DudokdeWit Chr. Fibrinolyse. Drukkerij Scheltema en Holkema-Amsterdam. 1962
    PubMedGoogle Scholar
  • 10 Fearnly G. R, Ferguson J, Chakrabarti R, Vincent C. T. Effect of beer on blood fibrinolytic activity. Lancet. I: 184 1960;
    PubMedGoogle Scholar
  • 11 Fischbacker W. Beitrag zur Fibrinolyse. Inaugural Dissertation. Buchdruckerei Walter Plüss. Zürich. 1960
    PubMedGoogle Scholar
  • 12 Fletcher A. P, Alkjaersig N, Sherry S. The clearance of heterologous protein from the circulation of normal and immunized man. J. clin. Invest. 37: 1306 1958;
    CrossrefPubMedGoogle Scholar
  • 13 Holemans R, Gross R. Influence of the blood platelets on fibrinolysis. Throm-bos. Diathes. haemorrh. (Stuttg..) 06: 196 1961;
    PubMedGoogle Scholar
  • 14 Horejsi J, Smetana R. The isolation of gamma globulin from blood serum by Rivanol. Acta med. scand. 145: 65 1956;
    PubMedGoogle Scholar
  • 15 Jacobsson K. Studies on trypsin and plasmininhibitors in human blood serum. Scand. J. clin. Lab. Invest.. 07. suppl. 14 1955
    PubMedGoogle Scholar
  • 16 Johnson S. A, Schneider C. L. The existence of antifibrinolytic activity in platelets. Science. 117: 229 1953;
    CrossrefPubMedGoogle Scholar
  • 17 Kaplan M. H. Studies of streptococcal fibrinolysis. J. clin. Invest. 25: 331 1946;
    CrossrefPubMedGoogle Scholar
  • 18 von Kaulla K. N, Schultz R. L. Methods for the evaluation of human fibrinolysis. Amer. J. clin. Path. 29: 104 1958;
    PubMedGoogle Scholar
  • 19 Kowalski E, Kopec M, Niewiarowski S. An evaluation of the euglobulin method for the determination of fibrinolysis. J. clin. Path. 12: 215 1959;
    CrossrefPubMedGoogle Scholar
  • 20 Marx R. Wirkungsweise der Fibrinolytika und Antifibrinolytika. —Experimentelle und therapeutische Fibrinolyse. V. Hamburger Symposion über Blutgerinnung. Thrombos. Diathes. haemorrh. (Stuttg). Suppl. 3 1962
    PubMedGoogle Scholar
  • 21 Milstone H. A factor in normal human blood which precipitates in streptococcal fibrinolysis. J. Immunol. 42: 109 1941;
    PubMedGoogle Scholar
  • 22 Moers A. M. J. De meting van fibrinolyse. Thesis, Amsterdam. 1962
    PubMedGoogle Scholar
  • 23 Müllertz S. Effect of carboxylic and amino-acids on fibrinolysis produced by plasmin, plasminogen activator and proteases. Proc. Soc. exp. Biol. 85: 326 1954;
    CrossrefPubMedGoogle Scholar
  • 24 de Nicola P, Soardi F, Gibelli A. Die antifibrinolytische Wirkung der epsilon-Aminocapronsäure. Schweiz, med. Wschr. 90: 1256 1960;
    PubMedGoogle Scholar
  • 25 Nilsson I. M, Björkman S. E, Anderson L. Clinical experience with epsilon-aminocaproic acid (epsilon ACA) as an antifibrinolytic agent. Acta med. Scand. 170: 487 1961;
    PubMedGoogle Scholar
  • 26 Nilsson I. M, Krook H, Sternby N. H, Söderberg E, Söderström N. Severe thrombotic disease in a young man with bone marrow and skeletal change and with a high content of an inhibitor on the fibrinolytic system. Acta med. Scand. 169: 323 1961;
    PubMedGoogle Scholar
  • 27 Nilsson I. M, Björkman S. E, Studnitz W. v, Hallen A. Antifibrinolytic activity of certain pectins. Thrombos. Diathes. haemorrh. (Stuttg..) 06: 177 1961;
    PubMedGoogle Scholar
  • 28 Norman P. S, Hill B. M. Physical properties of the two plasmin inhibitors in plasma. J. exp. Med. 108: 639 1958;
    CrossrefPubMedGoogle Scholar
  • 29 Norman P. S. Studies on the plasmin system. Inhibition of plasmin by serum or plasma. J. exp. Med. 108: 53 1958;
    PubMedGoogle Scholar
  • 30 Norman P. S. Some aspects of the chemistry of plasmin and its inhibitors. Am. J. Cardiol. 06: 390 1960;
    CrossrefPubMedGoogle Scholar
  • 31 Rasmussen J, Astrup T, Geill T. The fibrinolytic activity in blood from old patients. Proc. of the Vlllth Congress of the European Society of Haematology. Wien. 1961
    PubMedGoogle Scholar
  • 32 Ratnoff O. D, Lepow I. H, Pillemer L. The multiplicity of plasmin inhibitors in human serum demonstrated by the effect of primary amino-compounds. Bull. Johns Hopk. Hosp. 94: 169 1954;
    PubMedGoogle Scholar
  • 33 Sandberg H, Tsitouris T, Deleon A. C. Bellet Studies on inhibition to the plasmin-plasminogen fibrinolytic enzymes in patients with myocardial infarction. Amer. J. Cardiol. 05: 666 1960;
    CrossrefPubMedGoogle Scholar
  • 34 Shulman N. R. I. Studies on the inhibition of proteolytic enzymes by serum. II. Demonstration that separate proteolytic inhibitors exist in serum, their distinctive properties and their specificity of action. J. exp. Med. 95: 593 1952;
    PubMedGoogle Scholar
  • 35 Stefanini M, Murphey I. S. Human platelets as source of antifibrinolysin. J. clin. Invest. 35: 355 1956;
    CrossrefPubMedGoogle Scholar
  • 36 Tagnon H. J, Davidson Ch. S, Taylor F. H. L. Studies on blood coagulation. A proteolytic enzyme prepared from calcium and platelet free normal human blood plasmt. J. clin. Invest. 21: 511 1942;
    PubMedGoogle Scholar
  • 37 Tservrenis H, Mandalaki T, Giorgas D, Tsolas O. Activité pla-quettaire sérique étudiée par électrophorèse sur papier. Proc. of the VUIth Congress of the European Society of Haematology. Wien. 1961
    PubMedGoogle Scholar
  • 38 de Vries S. I, Braat-van Straaten M. A. J, Wettermark ME Müller en. Fibrinolyse door ontbreken van antifibrinolysine — een vorm van thrombopathie. Ned. T. Geneesk. 105: 1623 1961;
    PubMedGoogle Scholar
  • 39 de Vries S. I, Braat-van Straaten M. A. J, Müller E, Wettermark M. Antiplasmin deficiency in polycythemia, a form of thrombopathy. Thrombos. Diathes. haemorrh. (Stuttg..) 06: 445 1961;
    PubMedGoogle Scholar
  • 40 de Vries S. I, Braat-van Straaten M. A. J, Müller E. De invloed van enkele plantaardige produkten op het fibrinolytisch procès. Ned. T. Geneesk. 106: 1840 1962;
    PubMedGoogle Scholar